Provide first-to-market recombinant proteins and enzymes to accelerate novel biopharma and cell & gene therapy breakthroughs.
Established in 2018, KACTUS embarked on its journey with a resolute mission: deliver innovative recombinant protein solutions to address the unmet demands of researchers and the challenges posed by intricate protein expression. Today, our solutions have expanded to include 2500+ recombinant proteins, 25+ GMP enzymes, and custom protein expression. We continue to launch new products and services to facilitate novel drug development, focusing on current challenges in R&D and commercialization.
We gladly support you by keeping you updated on our latest products and the developments around our services.
